# Does Rosuvastatin Delay Progression of Atherosclerosis in HIV

> **NCT01813357** · PHASE4 · COMPLETED · sponsor: **Bayside Health** · enrollment: 84 (actual)

## Conditions studied

- HIV
- Cardiovascular Disease

## Interventions

- **DRUG:** Rosuvastatin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01813357
- **Lead sponsor:** Bayside Health
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07-02
- **Primary completion:** 2018-05-17
- **Final completion:** 2018-11-01
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2020-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01813357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01813357, "Does Rosuvastatin Delay Progression of Atherosclerosis in HIV". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01813357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*